Lantheus Holdings (LNTH) to Present New Data from First Phase 3 Study of Flurpiridaz F 18 for MPI Patients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Lantheus to Present New Data at the ASNC Annual Scientific Session on the Novel PET Cardiac Imaging Agent Flurpiridaz F 18 in Patients with Suspected Heart Disease Undergoing Exercise Stress Testing
September 22, 2016 4:19 PM EDTFindings Show Superiority of Flurpiridaz F 18 PET MPI Compared to SPECT MPI for the Assessment of Coronary Artery Disease During Exercise Stress Testing
NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Â Lantheus Holdings, Inc. (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (LMI), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents, today announced that new data from a sub-analysis of its first Phase 3 study of... More
